Page 20 - 2020_02-Haematologica-web

Editorials
References
1. Perales MA, Tomlinson B, Zhang MJ, et al. Alternative donor trans- plantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical Donor? Haematologica. 2019;105(2):407-413.
2. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971-1977.
3. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA- well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytoge- netics at diagnosis. Blood. 2010;116(11):1839-1848.
4. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-348.
5. Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor char- acteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260-267.
6. Shaw BE, Logan BR, Spellman SR, et al. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biol Blood Marrow Transplant. 2018;24(5):1049-1056.
7. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using non- myeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641- 650.
8. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical trans- plant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
9. Ciurea SO, Bittencourt MCB, Milton DR, et al. Is a matched unrelat- ed donor search needed for all allogeneic transplant candidates? Blood Adv. 2018;2(17):2254-2261.
10. Eapen M, Brazauskas R, Hemmer M, et al. Hematopoietic cell trans- plant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2(16):2095-2103.
11. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35(11):1154-1161.
12. Solomon SR, St Martin A, Shah NN, et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematolog- ic malignancy. Blood Adv. 2019;3(19):2836-2844.
13. Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation
Cyclophosphamide in Older Adults. J Clin Oncol. 2015;33(28):3152-
3161.
14. Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical
Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018;24(6):1232-1236.
15. Bashey ZA, Zhang X, Brown S, et al. Comparison of outcomes fol- lowing transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant. 2018;53(6):756-763.
16. Nagler A, Ruggeri A. Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2019;54(Suppl 2):713-718.
17. Mielcarek M, Furlong T, O'Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502-1508.
18. El Fakih R, Hashmi SK, Ciurea SO, Luznik L, Gale RP, Aljurf M. Post- transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2019 May 14. [Epub ahead of print]
19. Mehta RS, Saliba RM, Chen J, et al. Post-transplantation cyclophos- phamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016;173(3):444-455.
20. Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidenti- cal vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826-1836.
21. Copelan OR, Sanikommu SR, Trivedi JS, et al. Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. Biol Blood Marrow Transplant. 2019;25(4):785-790.
22. Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post- Transplant Cyclophosphamide. J Clin Oncol. 2017;35(26):3002- 3009.
23. Ciurea SO, Thall PF, Milton DR, et al. Complement-Binding Donor- Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(8):1392-1398.
24. Ciurea SO, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem- cell transplantation. Transplantation. 2009;88(8):1019-1024.
25. Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor- directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115(13):2704-2708.
254
haematologica | 2020; 105(2)